Literature DB >> 26611471

Concomitant gain of 1q21 and MYC translocation define a poor prognostic subgroup of hyperdiploid multiple myeloma.

Niels Weinhold1, Desiree Kirn2, Anja Seckinger3, Thomas Hielscher4, Martin Granzow2, Uta Bertsch3, Gerlinde Egerer3, Hans Salwender5, Igor W Blau6, Katja Weisel7, Jens Hillengass3, Marc S Raab3, Dirk Hose8, Hartmut Goldschmidt8, Anna Jauch2.   

Abstract

Entities:  

Keywords:  MYC rearrangements; cytogenetics and molecular genetics; multiple myeloma; outcome

Mesh：

Substances：

Year:  2015        PMID： 26611471      PMCID： PMC4815741          DOI： 10.3324/haematol.2015.136929

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  9 in total

1.  Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myélome.

Authors:  Hervé Avet-Loiseau; Michel Attal; Philippe Moreau; Catherine Charbonnel; Frédéric Garban; Cyrille Hulin; Serge Leyvraz; Mauricette Michallet; Ibrahim Yakoub-Agha; Laurent Garderet; Gérald Marit; Lucienne Michaux; Laurent Voillat; Marc Renaud; Bernard Grosbois; Gaelle Guillerm; Lotfi Benboubker; Mathieu Monconduit; Catherine Thieblemont; Philippe Casassus; Denis Caillot; Anne-Marie Stoppa; Jean-Jacques Sotto; Marc Wetterwald; Charles Dumontet; Jean-Gabriel Fuzibet; Isabelle Azais; Véronique Dorvaux; Marc Zandecki; Régis Bataille; Stéphane Minvielle; Jean-Luc Harousseau; Thierry Facon; Claire Mathiot
Journal:  Blood       Date:  2007-01-05       Impact factor: 22.113

Review 2.  Advances in the pathogenesis and diagnosis of multiple myeloma.

Authors:  M Chesi; P L Bergsagel
Journal:  Int J Lab Hematol       Date:  2015-05       Impact factor: 2.877

3.  Rearrangements of the c-myc oncogene are present in 15% of primary human multiple myeloma tumors.

Authors:  H Avet-Loiseau; F Gerson; F Magrangeas; S Minvielle; J L Harousseau; R Bataille
Journal:  Blood       Date:  2001-11-15       Impact factor: 22.113

4.  Impact of C-Myc gene-related aberrations in newly diagnosed myeloma with bortezomib/dexamethasone therapy.

Authors:  Naohiro Sekiguchi; Kaori Ootsubo; Miyuki Wagatsuma; Kiyoe Midorikawa; Akihisa Nagata; Satoshi Noto; Kazuaki Yamada; Naoki Takezako
Journal:  Int J Hematol       Date:  2014-02-05       Impact factor: 2.490

5.  Jumping translocations of 1q12 in multiple myeloma: a novel mechanism for deletion of 17p in cytogenetically defined high-risk disease.

Authors:  Jeffrey R Sawyer; Erming Tian; Christoph J Heuck; Joshua Epstein; Donald J Johann; Charles M Swanson; Janet L Lukacs; Marian Johnson; Regina Binz; Angela Boast; Gael Sammartino; Saad Usmani; Maurizio Zangari; Sarah Waheed; Frits van Rhee; Bart Barlogie
Journal:  Blood       Date:  2014-02-04       Impact factor: 22.113

6.  APOBEC family mutational signatures are associated with poor prognosis translocations in multiple myeloma.

Authors:  Brian A Walker; Christopher P Wardell; Alex Murison; Eileen M Boyle; Dil B Begum; Nasrin M Dahir; Paula Z Proszek; Lorenzo Melchor; Charlotte Pawlyn; Martin F Kaiser; David C Johnson; Ya-Wei Qiang; John R Jones; David A Cairns; Walter M Gregory; Roger G Owen; Gordon Cook; Mark T Drayson; Graham H Jackson; Faith E Davies; Gareth J Morgan
Journal:  Nat Commun       Date:  2015-04-23       Impact factor: 14.919

7.  Translocations at 8q24 juxtapose MYC with genes that harbor superenhancers resulting in overexpression and poor prognosis in myeloma patients.

Authors:  B A Walker; C P Wardell; A Brioli; E Boyle; M F Kaiser; D B Begum; N B Dahir; D C Johnson; F M Ross; F E Davies; G J Morgan
Journal:  Blood Cancer J       Date:  2014-03-14       Impact factor: 11.037

8.  Promiscuous MYC locus rearrangements hijack enhancers but mostly super-enhancers to dysregulate MYC expression in multiple myeloma.

Authors:  P Leif Bergsagel; W Michael Kuehl; Maurizio Affer; Marta Chesi; Wei-Dong G Chen; Jonathan J Keats; Yulia N Demchenko; Anna V Roschke; Scott Van Wier; Rafael Fonseca
Journal:  Leukemia       Date:  2014-02-12       Impact factor: 11.528

9.  The CCND1 c.870G>A polymorphism is a risk factor for t(11;14)(q13;q32) multiple myeloma.

Authors:  Niels Weinhold; David C Johnson; Daniel Chubb; Bowang Chen; Asta Försti; Fay J Hosking; Peter Broderick; Yussanne P Ma; Sara E Dobbins; Dirk Hose; Brian A Walker; Faith E Davies; Martin F Kaiser; Ni L Li; Walter A Gregory; Graham H Jackson; Mathias Witzens-Harig; Kai Neben; Per Hoffmann; Markus M Nöthen; Thomas W Mühleisen; Lewin Eisele; Fiona M Ross; Anna Jauch; Hartmut Goldschmidt; Richard S Houlston; Gareth J Morgan; Kari Hemminki
Journal:  Nat Genet       Date:  2013-03-17       Impact factor: 38.330
  9 in total
  14 in total

1.  Additional-structural-chromosomal aberrations are associated with inferior clinical outcome in patients with hyperdiploid multiple myeloma: a single-institution experience.

Authors:  Adrian A Carballo-Zarate; L Jeffrey Medeiros; Lianghua Fang; Jatin J Shah; Donna M Weber; Sheeba K Thomas; Elisabet E Manasanch; Suyang Hao; Qi Shen; Robert Z Orlowski; Pei Lin; Xinyan Lu
Journal:  Mod Pathol       Date:  2017-03-10       Impact factor: 7.842

Review 2.  Genomic complexity of multiple myeloma and its clinical implications.

Authors:  Salomon Manier; Karma Z Salem; Jihye Park; Dan A Landau; Gad Getz; Irene M Ghobrial
Journal:  Nat Rev Clin Oncol       Date:  2016-08-17       Impact factor: 66.675

3.  Cytogenetic subclone formation and evolution in progressive smoldering multiple myeloma.

Authors:  Maximilian Merz; Thomas Hielscher; David Schult; Elias K Mai; Marc S Raab; Jens Hillengass; Anja Seckinger; Dirk Hose; Martin Granzow; Anna Jauch; Hartmut Goldschmidt
Journal:  Leukemia       Date:  2019-11-11       Impact factor: 11.528

4.  Prognostic significance of cytogenetic heterogeneity in patients with newly diagnosed multiple myeloma.

Authors:  Maximilian Merz; Anna Jauch; Thomas Hielscher; Tilmann Bochtler; Stefan Olaf Schönland; Anja Seckinger; Dirk Hose; Uta Bertsch; Kai Neben; Marc Steffen Raab; Jens Hillengass; Hans Salwender; Igor Wolfgang Blau; Hans-Walter Lindemann; Ingo G H Schmidt-Wolf; Christof Scheid; Mathias Haenel; Katja C Weisel; Hartmut Goldschmidt
Journal:  Blood Adv       Date:  2017-12-27

5.  Clonal selection and double-hit events involving tumor suppressor genes underlie relapse in myeloma.

Authors:  Niels Weinhold; Cody Ashby; Leo Rasche; Shweta S Chavan; Caleb Stein; Owen W Stephens; Ruslana Tytarenko; Michael A Bauer; Tobias Meissner; Shayu Deshpande; Purvi H Patel; Timea Buzder; Gabor Molnar; Erich A Peterson; Frits van Rhee; Maurizio Zangari; Sharmilan Thanendrarajan; Carolina Schinke; Erming Tian; Joshua Epstein; Bart Barlogie; Faith E Davies; Christoph J Heuck; Brian A Walker; Gareth J Morgan
Journal:  Blood       Date:  2016-08-11       Impact factor: 22.113

6.  Longitudinal fluorescence in situ hybridization reveals cytogenetic evolution in myeloma relapsing after autologous transplantation.

Authors:  Maximilian Merz; Anna Jauch; Thomas Hielscher; Elias K Mai; Anja Seckinger; Dirk Hose; Uta Bertsch; Kai Neben; Marc S Raab; Hans Salwender; Igor W Blau; Hans-Walter Lindemann; Ingo Schmidt-Wolf; Christof Scheid; Mathias Haenel; Katja Weisel; Hartmut Goldschmidt; Jens Hillengass
Journal:  Haematologica       Date:  2017-05-11       Impact factor: 9.941

7.  Bi-allelic inactivation is more prevalent at relapse in multiple myeloma, identifying RB1 as an independent prognostic marker.

Authors:  S S Chavan; J He; R Tytarenko; S Deshpande; P Patel; M Bailey; C K Stein; O Stephens; N Weinhold; N Petty; D Steward; L Rasche; M Bauer; C Ashby; E Peterson; S Ali; J Ross; V A Miller; P Stephens; S Thanendrarajan; C Schinke; M Zangari; F van Rhee; B Barlogie; T I Mughal; F E Davies; G J Morgan; B A Walker
Journal:  Blood Cancer J       Date:  2017-02-24       Impact factor: 11.037

8.  A multiple myeloma-specific capture sequencing platform discovers novel translocations and frequent, risk-associated point mutations in IGLL5.

Authors:  Brian S White; Irena Lanc; Julie O'Neal; Harshath Gupta; Robert S Fulton; Heather Schmidt; Catrina Fronick; Edward A Belter; Mark Fiala; Justin King; Greg J Ahmann; Mary DeRome; Elaine R Mardis; Ravi Vij; John F DiPersio; Joan Levy; Daniel Auclair; Michael H Tomasson
Journal:  Blood Cancer J       Date:  2018-03-21       Impact factor: 11.037

9.  The Prognostic Role of MYC Structural Variants Identified by NGS and FISH in Multiple Myeloma.

Authors:  Neeraj Sharma; James B Smadbeck; Nadine Abdallah; Cinthya Zepeda-Mendoza; Moritz Binder; Kathryn E Pearce; Yan W Asmann; Jess F Peterson; Rhett P Ketterling; Patricia T Greipp; P Leif Bergsagel; S Vincent Rajkumar; Shaji K Kumar; Linda B Baughn
Journal:  Clin Cancer Res       Date:  2021-10-01       Impact factor: 12.531

10.  c-MYC expression and maturity phenotypes are associated with outcome benefit from addition of ixazomib to lenalidomide-dexamethasone in myeloma.

Authors:  Alessandra Di Bacco; Nizar J Bahlis; Nikhil C Munshi; Hervé Avet-Loiseau; Tamás Masszi; Luísa Viterbo; Ludek Pour; Peter Ganly; Michele Cavo; Christian Langer; Shaji K Kumar; S Vincent Rajkumar; Jonathan J Keats; Deborah Berg; Jianchang Lin; Bin Li; Sunita Badola; Lei Shen; Jacob Zhang; Dixie-Lee Esseltine; Katarina Luptakova; Helgi van de Velde; Paul G Richardson; Philippe Moreau
Journal:  Eur J Haematol       Date:  2020-04-15       Impact factor: 2.997
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.